We report here that novel anti-CTLA-4 and anti-PD-L1 immunomodulatory mAbs, previously generated in our laboratory, have greater anti-tumor activity than the clinically validated ipilimumab and atezolizumab on TNBC cells, well known for their aggressiveness and resistance to conventional chemotherapeutic treatments. This evidence concerns the gene CTLA4 and neoplasm.